نتائج البحث - "Marcelo Marotti"

1

دورية أكاديمية

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment

المؤلفون: Karthick Vishwanathan, Inmaculada Sanchez‐Simon, Bhumsuk Keam, Nicolas Penel, Maria deMiguel‐Luken, Doris Weilert, Andrew Mills, Marcelo Marotti, Martin Johnson, Alain Ravaud

المصدر: Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)

مصطلحات موضوعية: epidermal growth factor receptors, kidney, non‐small cell lung cancer, osimertinib, pharmacokinetics, renal disposition, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2052-1707

URL الوصول: https://doaj.org/article/3def02ff83134171b001fbbb4b3c90e2

View record at Wiley

Find this article in full text from ProQuest

Full Text Finder

2

Paediatric Strategy Forum for medicinal product development in mitogen-activated protein kinase pathway inhibitors

المصدر: European Journal of Cancer. 177:120-142

مصطلحات موضوعية: Cancer Research, Oncology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::e51cb81f4e064a01a1e1d2c5bc7d4f56
https://doi.org/10.1016/j.ejca.2022.09.036

View record from ScienceDirect

Full Text via ClinicalKey

3

Supplementary Figure 1 from Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma

المؤلفون: Michael Leahy, Juliane M. Jürgensmeier, Helen Young, Barbara Collins, Marcelo Marotti, Elizabeth Barquin, Kate Gardner, Michelle Scurr, Ian Judson

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbe4a8a7926ade19c45e49d5cc136949
https://doi.org/10.1158/1078-0432.22450013.v1

4

Data from Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma

المؤلفون: Michael Leahy, Juliane M. Jürgensmeier, Helen Young, Barbara Collins, Marcelo Marotti, Elizabeth Barquin, Kate Gardner, Michelle Scurr, Ian Judson

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24b1fab8490740a3e5c7f242d3e7985e
https://doi.org/10.1158/1078-0432.c.6521825

5

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

المؤلفون: Naoyuki Nogami, Martine P. Roudier, Marcelo Marotti, Laura Q.M. Chow, Tammie C. Yeh, Don L. Gibbons, Mei Tang, Shintaro Kanda, Weifeng Tang, Rosemary Taylor, Sang We Kim, Helen K. Angell, Benjamin C. Creelan, Dong Wan Kim

المصدر: British Journal of Cancer

مصطلحات موضوعية: Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Durvalumab, Lung Neoplasms, Cancer immunotherapy, Article, Tumour biomarkers, 03 medical and health sciences, 0302 clinical medicine, Gefitinib, Targeted therapies, Pharmacokinetics, Internal medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, medicine, Humans, Progression-free survival, Lung cancer, Aged, Aged, 80 and over, business.industry, Antibodies, Monoclonal, Middle Aged, medicine.disease, Progression-Free Survival, respiratory tract diseases, Clinical trial, ErbB Receptors, 030220 oncology & carcinogenesis, Toxicity, Mutation, Female, business, Non-small-cell lung cancer, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::448e3a9b7d0095214e38cb20071b4a7f
http://europepmc.org/articles/PMC7852511

Find this article in full text from ProQuest

6

Abstract 2667: Trial in progress: Phase 1 study of BI 1823911, an irreversible KRASG12C inhibitor targeting KRAS in its GDP-loaded state, as monotherapy and in combination with the pan-KRAS SOS1 inhibitor BI 1701963 in solid tumors expressing KRASG12C mutation

المؤلفون: Irene C. Waizenegger, Hengyu Lu, Claus Thamer, Fabio Savarese, Daniel Gerlach, Dorothea Rudolph, Christopher P. Vellano, Marcelo Marotti, John Heymach, Scott Kopetz, Timothy P. Heffernan, Joseph R. Marszalek, Mark P. Petronczki, Marco H. Hofmann, Norbert Kraut

المصدر: Cancer Research. 82:2667-2667

مصطلحات موضوعية: Cancer Research, Oncology

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::82b54535c8ce6e057818ea3d3d58241e
https://doi.org/10.1158/1538-7445.am2022-2667

7

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment

المؤلفون: Nicolas Penel, Karthick Vishwanathan, Alain Ravaud, Bhumsuk Keam, Martin Johnson, Inmaculada Sanchez-Simon, Maria de Miguel-Luken, Doris Weilert, Andrew Mills, Marcelo Marotti

المصدر: Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)

مصطلحات موضوعية: Male, renal disposition, Administration, Oral, Kidney Function Tests, Severity of Illness Index, 030226 pharmacology & pharmacy, 0302 clinical medicine, Neoplasms, tyrosine kinase inhibitors, Osimertinib, General Pharmacology, Toxicology and Pharmaceutics, Aged, 80 and over, Kidney, education.field_of_study, Aniline Compounds, Middle Aged, medicine.anatomical_structure, Neurology, Area Under Curve, osimertinib, 030220 oncology & carcinogenesis, Female, Original Article, pharmacokinetics, non‐small cell lung cancer, kidney, medicine.medical_specialty, Population, Cmax, Urology, Renal function, Antineoplastic Agents, RM1-950, 03 medical and health sciences, Pharmacokinetics, medicine, Hepatic Insufficiency, Humans, Dosing, education, Protein Kinase Inhibitors, non-small cell lung cancer, Aged, Acrylamides, business.industry, Cancer, Original Articles, medicine.disease, epidermal growth factor receptors, Therapeutics. Pharmacology, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36dfb55310a91895d57f00b9e21d0c92
https://doi.org/10.1002/prp2.613

View record at Wiley

Find this article in full text from ProQuest

8

Frequenz von EGFR (epidermaler Wachstumsfaktorrezeptor)-Mutationen im Stadium IB-IIIA NSCLC nach kompletter Tumorresektion

المؤلفون: Jea Miziara, Thomas John, Dariusz M. Kowalski, G. Laus, A. Öztürk, C. Yu, W Engel-Riedel, Damien Urban, C. Akewanlop, Jonathan H. Goldman, A Rittmeyer, M. Majem, Roy S. Herbst, Yi-Long Wu, Sang We Kim, B.V. Quang, Masahiro Tsuboi, Silvia Novello, Marcelo Marotti, D. Marmol

المصدر: 61. Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin e.V..

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::728310cc6bd8886d94b5b1b7547167a5
https://doi.org/10.1055/s-0039-3403361

9

Abstract CT210: Trial in Process: Phase 1 studies of BI 1701963, a SOS1::KRAS Inhibitor, in combination with MEK inhibitors, irreversible KRASG12C inhibitors or irinotecan

المؤلفون: Timothy P. Heffernan, Annette Machado, Ulrich Duenzinger, Joseph R. Marszalek, Christopher P. Vellano, Michael Gmachl, Mark Petronczki, Dorothea Rudolph, Daniel Gerlach, Marco H. Hofmann, Francesca Trapani, Vitomir Vucenovic, Norbert Kraut, Marcelo Marotti, Joseph R. Daniele, Irene Waizenegger, Hengyu Lu

المصدر: Cancer Research. 81:CT210-CT210

مصطلحات موضوعية: Trametinib, Cancer Research, Colorectal cancer, business.industry, Cancer, medicine.disease, medicine.disease_cause, digestive system diseases, Irinotecan, Oncology, Tolerability, medicine, Cancer research, SOS1, Adenocarcinoma, KRAS, business, neoplasms, medicine.drug

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::5aba2ef95ed853c38d2a3066731e6927
https://doi.org/10.1158/1538-7445.am2021-ct210

10

Frequency of epidermal growth factor receptor (EGFR) mutations in stage IB–IIIA EGFR mutation positive non-small cell lung cancer (NSCLC) after complete tumour resection

المؤلفون: Jonathan W. Goldman, Damien Urban, C. Akewanlop, Roy S. Herbst, Masahiro Tsuboi, J.E.A. Miziara, G. Laus, B.V. Quang, Silvia Novello, Marcelo Marotti, C. Yu, A. Öztürk, D. Marmol, C. Grohe, M. Majem, Y-L. Wu, Dariusz M. Kowalski, Sang We Kim, Thomas John

المصدر: Annals of Oncology. 30:v589

مصطلحات موضوعية: medicine.medical_specialty, business.industry, Adjuvant chemotherapy, Tumor resection, non-small cell lung cancer (NSCLC), Hematology, medicine.disease, EGFR Gene Mutation, Complete resection, Stage ib, Oncology, Egfr mutation, Family medicine, Medicine, Osimertinib, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::cab05a3cd920d807426569e01becfa1f
https://doi.org/10.1093/annonc/mdz258.010

تنقيح النتائج